Quick Summary

Rehmannia glutinosa is a traditional Chinese medicinal herb commonly used in compound formulations for various health conditions including Graves’ disease, perimenopausal syndrome in breast cancer patients, diabetic nephropathy, and other chronic diseases. It contains bioactive constituents such as iridoid glycosides (notably catalpol) and polysaccharides, which have diverse pharmacological potentials. Clinical evidence suggests some potential immunomodulatory, metabolic, and vascular benefits, though most studies involve Rehmannia as part of multi-herb formulations or combined with conventional treatments. Safety data are limited but no serious adverse effects have been reported in randomized controlled trials evaluating compound prescriptions containing Rehmannia. Overall, evidence quality is limited by methodological flaws and heterogeneity. Further large-scale, high-quality clinical trials are needed to better define its effects and safety profile.

What Is It?

Rehmannia glutinosa is a perennial herbaceous plant native to China, valued in traditional Chinese medicine (TCM). Its roots are the primary medicinal part, used dried or processed in herbal formulations. The plant is classified botanically in the Orobanchaceae family and has been used for centuries in TCM to address various systemic conditions.

Traditional Uses

  • Treating thyroid-related disorders such as Graves’ disease
  • Managing perimenopausal symptoms, especially in breast cancer patients
  • Supporting kidney function in diabetic nephropathy
  • Addressing metabolic, hormonal, and immune regulation imbalances
  • Used as a component in complex herbal prescriptions for chronic diseases including hypothyroidism, diabetic osteoporosis, and immune thrombocytopenia

Active Compounds

Rehmannia contains several bioactive compounds, including:

  • Iridoid glycosides – such as catalpol, which is studied for diverse pharmacological actions
  • Polysaccharides – noted for their potential immunomodulatory and metabolic effects

Potential Benefits with Evidence Levels

Immune Function Improvement in Graves’ Disease

A meta-analysis of 44 randomized controlled trials (RCTs) suggests that Chinese herbal compound prescriptions containing Rehmannia may improve immune-related markers and thyroid function in Graves’ disease patients, with fewer adverse reactions compared to Western medicine alone.

Evidence Level: Moderate (limited by heterogeneity and multi-herb formula use)
PMID: 41956233

Treatment of Perimenopausal Syndrome in Breast Cancer Patients

A meta-analysis of 17 RCTs involving 1,139 patients found that Chinese herbal medicine with Rehmannia as a principal herb improved the Kupperman index, overall performance status, and peripheral T-cell profiles without severe adverse effects compared to Western medicines.

Evidence Level: Low to Moderate (due to methodological limitations and heterogeneity)
PMID: 40628433

Adjunct Treatment for Diabetic Nephropathy

Meta-analysis of 13 RCTs with 1,333 participants suggests that Jinlida granules, which contain Rehmannia, may help improve renal function and metabolic parameters as an adjunct therapy in diabetic nephropathy, with no significant increase in adverse events compared to controls.

Evidence Level: Low to Moderate (heterogeneity and limited safety data)
PMID: 41767388

Potential Benefits in Other Conditions

Rehmannia is a core herb in multiple traditional Chinese medicine formulas used for hypothyroidism, diabetic osteoporosis, immune thrombocytopenia, and other conditions. Evidence mainly comes from preclinical studies and clinical trials involving herb combinations, indicating possible immune regulation, metabolic modulation, and hormonal effects.

Evidence Level: Preliminary to insufficient clinical evidence
References:
PMID: 41889672,
PMID: 41507972,
PMID: 41929773,
PMID: 41788627

Side Effects

No serious adverse effects have been reported in clinical trials involving formulas containing Rehmannia. Some mild gastrointestinal symptoms and other minor adverse events were noted but occurred less frequently than in comparator groups.

Drug Interactions

There is no direct clinical evidence of specific drug interactions involving Rehmannia glutinosa. Nevertheless, caution is advised when using Rehmannia-containing products alongside conventional pharmacotherapy due to limited data.

Who Should Avoid It

  • Individuals who are pregnant or breastfeeding should avoid use unless supervised by a healthcare professional, as safety data are lacking.
  • People with severe systemic illnesses should follow standard precautions for herbal use.
  • No specific contraindications identified from existing clinical trial data.

Evidence Limitations

  • Most clinical studies assess Rehmannia as part of multi-herb formulas, making it difficult to isolate herb-specific effects.
  • Many studies have methodological shortcomings, small sample sizes, and high heterogeneity.
  • Safety data are limited and often under-reported.
  • Few high-quality, large-scale randomized controlled trials solely focused on Rehmannia glutinosa exist.
  • Lack of long-term follow-up and mechanistic studies in humans.

References

Last Reviewed

June 2024

Information Disclaimer: This page is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new treatment, especially when using herbal products or supplements. The evidence summarized here does not guarantee efficacy or safety, and individual responses may vary.